News Takeda buys coeliac drug licence from COUR Pharmaceuticals Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
